Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 6, 2008, Pages 718-721

  Zuberbier, Torsten ^a   Brautigam M ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

Author keywords

Atopic dermatitis; Face; Pimecrolimus

Indexed keywords

DRUG VEHICLE; EMOLLIENT AGENT; PIMECROLIMUS; PREDNICARBATE;

ADOLESCENT; APPLICATION SITE BURNING; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREAM; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HERPES SIMPLEX; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOLLUSCUM CONTAGIOSUM; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCRATCHING; SKIN SENSITIVITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FACE; HUMANS; TACROLIMUS; TREATMENT OUTCOME;

EID: 43649090235     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2008.02586.x     Document Type: Article

References (15)

1. Wellington K, Jarvis B. Topical pimecrolimus. A review of its clinical potential in the management of atopic dermatitis. Drugs 2002; 62: 817-840.
2. Papp KA, Werfel T, Fölster-Holst R et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants: A 2-year study. J Am Acad Dermatol 2005; 52: 240-246.
3. Grassberger M, Steinhoff M, Schneider D, Luger T. Pimecrolimus - an anti-inflammatory drug targeting the skin. J Exp Dermatol 2004; 13: 721-730.
4. Gupta AK, Chow M. Pimecrolimus. A review. J Eur Acad Dermatol Venereol 2003; 17: 493-503.
5. Wahn U, Bos JD, Goodfield M et al., for the free (children) multicenter investigator group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: E2.
6. Meurer M, Fölster-Holst R, Wozel G et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in adults: A six-month study. Dermatology 2002; 205: 271-277.
7. Kapp A, Papp K, Bingham A et al. Efficacy and safety of pimecrolimus cream, a novel non-steroid anti-inflammatory, in long-term management of atopic dermatitis in infants. J Allergy Clin Immunol 2002; 110: 277-278.
8. Zuberbier T, Heinzerling L, Bieber T et al. Steroid sparing potential of pimecrolimus cream 1% in children with severe atopic dermatitis. Dermatology 2007: 215: 325-330.
9. Cork MJ, Robinson D, Vasilopoulos Y et al. Predisposition to sensitive skin and atopic eczema. Community Practitioner 2005; 78: 440-442.
10. Del Rosso J, Friedlander SF. Corticosteroids: Options in the era of steroid-sparing therapy. J Am Acad Dermatol 2005; 53: S50-S58.
11. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticoids. J Am Acad Dermatol 2006; 54: 1-15.
12. Cork M, Robinson D, Vasilopoulos Y, Ferguson A. Interaction of topical corticosteroids and pimecrolimus with the skin barrier. implications for efficacy and safety of treatment for atopic dermatitis. J Am Acad Dermatol 2006; 54 (Suppl. S): AB3, P10.
13. Drake LA, Dinehart SM, Farmer ER, Goltz RW et al. Guidelines of care for the use of topical glucocorticosteroids. J Am Acad Dermatol 1996; 35: 616-619.
14. Queille-Roussel C, Paul C, Duteil L et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507-513.
15. De Backer M, Lambert J, Degreef H, Lesaffre E. Belgian drug utilization study of pimecrolimus cream 1% in routine practice in atopic dermatitis. J Am Acad Dermatol 2007; 56 (Suppl. 2): AB 70.